Valuation: Moderna, Inc.

Market Cap 25.14B 21.56B 20.13B 18.47B 34.74B 2,403B 35.31B 238B 93.03B 1,205B 94.38B 92.33B 3,984B P/E 2026 *
-7.34x
P/E 2027 * -12.8x
Enterprise Value 21.49B 18.43B 17.21B 15.79B 29.69B 2,054B 30.18B 203B 79.52B 1,030B 80.68B 78.92B 3,406B EV / Sales 2026 *
10.2x
EV / Sales 2027 * 9.42x
Free-Float
92.68%
Yield 2026 *
-
Yield 2027 * -
1 day+130.65%
1 week+128.08%
Current month+164.90%
1 month+144.11%
3 months+217.63%
6 months+192.19%
Current year+392.44%
1 week 60.82
Extreme 60.82
163.47
1 month 52.66
Extreme 52.6601
163.47
Current year 29.81
Extreme 29.81
163.47
1 year 22.28
Extreme 22.28
163.47
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
464.85
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2011
Director of Finance/CFO 49 05/09/2022
President 50 31/10/2024
Director TitleAgeSince
Chairman 63 31/01/2012
Director/Board Member 54 28/02/2011
Director/Board Member 69 10/12/2019
Date Insider Type Main position Quantity % Market Cap.
06/08/26 Fiscal year

Chief Executive Officer

504,938 0.1273%
15/07/26 Fiscal year

Chairperson

160,008 0.0403%
08/07/26 Free

Director

14,766 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
+126.96%+128.08%+420.32%+30.73% 25.14B
+2.82%+4.59%+45.97%-1.15% 80.91B
+5.49%+20.35%-38.64%-38.47% 53.62B
+0.85%-4.04%-2.31%+30.25% 50.13B
+0.23%-1.80%+13.14%+167.24% 47.97B
+2.45%+4.55%+57.27%-17.61% 31.41B
+2.79%+4.85%+48.17%+95.18% 25.03B
+1.66%+2.83%-3.58%+212.40% 21.45B
+0.22%+4.68%+66.64%+126.90% 16.93B
+0.50%-0.51%+70.54%+191.64% 16.22B
Average +14.77%+2.72%+67.75%+79.71% 36.88B
Weighted average by Cap. +11.00%+2.89%+48.61%+53.68%

Financials

2026 *2027 *
Net sales 2.11B 1.81B 1.69B 1.55B 2.91B 201B 2.96B 19.91B 7.8B 101B 7.91B 7.74B 334B 2.43B 2.08B 1.95B 1.78B 3.36B 232B 3.41B 22.95B 8.99B 116B 9.12B 8.92B 385B
Net income -3.38B -2.9B -2.71B -2.48B -4.67B -323B -4.75B -31.94B -12.51B -162B -12.69B -12.41B -536B -1.92B -1.65B -1.54B -1.41B -2.66B -184B -2.7B -18.18B -7.12B -92.23B -7.22B -7.07B -305B
Net Debt -3.65B -3.13B -2.92B -2.68B -5.04B -349B -5.13B -34.49B -13.51B -175B -13.7B -13.4B -578B -2.27B -1.95B -1.82B -1.67B -3.14B -217B -3.19B -21.47B -8.41B -109B -8.53B -8.34B -360B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
19/08/26 US$145.33 +130.83% 117,781,167
18/08/26 US$62.96 -2.33% 4,304,996
17/08/26 US$64.46 +1.80% 3,979,550
14/08/26 US$63.32 -0.52% 4,700,891
13/08/26 US$63.65 -0.03% 8,159,738
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
62.96USD
Average target price
50.84USD
Spread / Average Target
-19.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock